CalciMedica receives Nasdaq approval, relisting starts June 14, 2023 under CALC

CalciMedica, Inc.

Nasdaq approved relisting on Capital Market; trading begins June 14, 2023.
Common stock to trade under ticker 'CALC' on Nasdaq after OTCQB trading.
CEO cites improved liquidity, broader investor access, and support for clinical strategy.
Company continues Phase 2 trials of Auxora for inflammatory diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.